Rhythm Pharmaceuticals
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that ca...
Latest News
11 hours ago · globenewswire.com
Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026– Two-year results from Phase 3 TRANSCEND trial showed continuous setmelanotide therapy sustained BMI reductions in patients with acquired hypothalamic obesity –
6 days ago · seekingalpha.com
Rhythm Pharmaceuticals: Bull Case Intact, But The Market Is Pricing In A LotRhythm Pharmaceuticals maintains strong commercial momentum, with IMCIVREE sales up 79.5% YoY and a broadening prescriber base in the acquired HO. RYTM's valuation is elevated at 27.4x trailing sales, reflecting high expectations for sustained growth and successful international launches. Takeover speculation, including a reported $124/share AstraZeneca bid, is supporting the share price but inflates the takeover premium over fundamentals.
14 days ago · seekingalpha.com
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2026 Earnings Call TranscriptRhythm Pharmaceuticals, Inc. (RYTM) Q3 2026 Earnings Call Transcript
14 days ago · marketbeat.com
Rhythm Pharmaceuticals Q3 Earnings Call HighlightsRhythm Pharmaceuticals NASDAQ: RYTM reported third-quarter global net product sales of $92.1 million, up 29% sequentially, as the company cited a strong early U.S. launch for IMCIVREE in acquired hypothalamic obesity, or acquired HO. The company also outlined plans to advance bivamelagon into Phase III studies for acquired HO and Prader-Willi syndrome, while expanding its international commercial footprint.
14 days ago · zacks.com
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue EstimatesRhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to a loss of $0.82 per share a year ago.
14 days ago · globenewswire.com
Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update-- Strong U.S. launch momentum for IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) continues with more than 700 patient start forms as of September 30, 2026 -- -- Third quarter 2026 net product revenue from global sales of IMCIVREE of $92.1 million, an increase of 29% from the prior quarter -- -- Commercial launch of IMCIVREE in Japan for patients with acquired HO underway -- -- Bivamelagon to advance into pivotal development in Prader-Willi syndrome --
14 days ago · globenewswire.com
Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement-- Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718 -- -- Rhythm to pay LG Chem additional fixed payments totaling $350 million over four years --
21 days ago · zacks.com
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseRhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
27 days ago · globenewswire.com
Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 3, 2026 to report its third quarter 2026 financial results and provide a corporate update.
1 month ago · zacks.com
Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should KnowRhythm Pharmaceuticals (RYTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove RYTM